'Atom Heart Mothers': the risk of ischaemic heart disease in women with adverse pregnancy outcomes
- PMID: 36942437
- DOI: 10.1093/eurheartj/ehad166
'Atom Heart Mothers': the risk of ischaemic heart disease in women with adverse pregnancy outcomes
Conflict of interest statement
Conflict of interest R.V. received speaker fees from Abbott Vascular, Amgen, and Terumo, outside the submitted work. C.P. received consultant and speaker fees from Acticor Biotech, Amgen, Bayer, Eli Lilly, Tremeau, Zambon, and grant support (to the Institution) for investigator-initiated research from AIFA (Italian Drug Agency), Bayer, Cancer Research UK, and European Commission; he chairs the Scientific Advisory Board of the International Aspirin Foundation.
Comment on
-
Adverse pregnancy outcomes and long term risk of ischemic heart disease in mothers: national cohort and co-sibling study.BMJ. 2023 Feb 1;380:e072112. doi: 10.1136/bmj-2022-072112. BMJ. 2023. PMID: 36724989 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
